Clinical trials: Libido Disorder
Sexual Dysfunctions, Psychological
Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder
The object of this trial is to assess the safety and efficacy of a 24 week course of flibanserin for the treatment of hypoactive sexual desire disorder in premenopausal women.
- Trial name
- NCT00996164
- Testing
- Flibanserin
- Where
- 75 sites in United States
- Volunteers
- 1,090 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Sexual Dysfunctions, Psychological
Pharmacokinetics of Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
This trial examines the way flibanserin is metabolized in postmenopausal women with Hypoactive Sexual Desire Disorder.
- Trial name
- NCT01188603
- Testing
- flibanserin 100 mg dose every evening
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Contraception, Libido
Effects of SH T00658ID on Libido
The aim of the study is to investigate whether women on oral contraceptives (OCs) suffering from acquired OC-associated female sexual dysfunction (FSD) for at least 3 months but no longer than one year will express the same level…
- Trial name
- NCT00764881
- Testing
- EV/DNG (Qlaira, BAY86-5027, SH T00658ID), Microgynon
- Where
- 32 sites in Australia, Austria and 5 more
- Volunteers
- 217 people
- Sponsor
- Bayer
Female Sexual Arousal Disorder, Hypoactive Sexual Desire Disorder
Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder
This trial is designed to evaluate the efficacy and safety of 3 fixed dose levels of bremelanotide, administered subcutaneously on an as-needed basis under conditions of home use, for the treatment of female sexual arousal…
- Trial name
- NCT01382719
- Testing
- bremelanotide
- Where
- 68 sites in United States, Canada
- Volunteers
- 612 people
- Sponsor
- Palatin Technologies, Inc
Sexual Dysfunctions, Psychological
Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women
The objective of this trial is to assess the safety and efficacy of 24-week course of flibanserin for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in naturally postmenopausal women.
- Trial name
- NCT00996372
- Testing
- flibanserin
- Where
- 75 sites in United States
- Volunteers
- 949 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Hypoactive Sexual Desire Disorder
1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an optional Open-label Extension to evaluate the efficacy of bremelanotide (BMT), administered subcutaneously (SC) on an as needed basis for the…
- Trial name
- HSDD (NCT02333071)
- Testing
- Bremelanotide
- Where
- 91 sites in United States, Canada
- Volunteers
- 723 people
- Sponsor
- Palatin Technologies, Inc
Hypoactive Sexual Desire Disorder
Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women
This study is designed to evaluate the endometrial safety of a testosterone patch as treatment for low libido in naturally postmenopausal women.
- Trial name
- NCT00467259
- Testing
- Testosterone Transdermal System
- Where
- 115 sites in United States
- Volunteers
- 1,271 people
- Sponsor
- Warner Chilcott
Sexual Dysfunctions, Psychological
Flibanserin Evaluation Over 28 Additional Weeks in Hypoactive Sexual Desire Disorder
Safety profile of flibanserin over 28 additional weeks Distribution of preferred dose regimens
- Trial name
- NCT00601367
- Testing
- flibanserin flexible dose
- Where
- 68 sites in Austria, Belgium and 10 more
- Volunteers
- 480 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Sexual Dysfunctions, Psychological
A One-year Safety Study of Flibanserin to Treat Pre-Menopausal Women With Hypoactive Sexual Desire Disorder (HSDD).
To determine if long-term treatment with Flibanserin is safe and to monitor the effectiveness of Flibanserin in Women with HSDD that have already completed a previous study (511.70/71/.74/.75/.105) with Flibanserin.
- Trial name
- NCT00441558
- Testing
- Flibanserin
- Where
- 196 sites in United States, Canada
- Volunteers
- 1,723 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Hypogonadism
A Study in Men With Low Testosterone to Measure the Effects of Testosterone Solution on Testosterone Levels, Sex Drive and Energy
The main purpose of this study is to evaluate if testosterone solution can raise testosterone hormone levels into the normal range, and also improve levels of sexual arousal, interest and drive and/or energy level, in men with…
- Trial name
- NCT01816295
- Testing
- Testosterone Solution
- Where
- 85 sites in United States, Argentina and 7 more
- Volunteers
- 715 people
- Sponsor
- Eli Lilly and Company
Sexual Dysfunctions, Psychological
A 28-week Safety Study of Flibanserin in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder
To generate additional long-term safety and efficacy data on flibanserin in premenopausal women and establish long-term safety and tolerability of flibanserin in naturally postmenopausal women with Hypoactive Sexual Desire…
- Trial name
- NCT01103362
- Testing
- flibanserin
- Where
- 95 sites in United States, Canada
- Volunteers
- 596 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Erectile Dysfunction
A Bioavailability Study of LY2452473 and Tadalafil
This study compares LY2452473 taken orally as a 5 milligram (mg) capsule at the same time as a 5 mg tadalafil tablet with three different combination tablets (LY900010) of 5 mg LY2452473 and 5 mg tadalafil taken orally.
- Trial name
- NCT01401543
- Testing
- LY2452473, Tadalafil, LY900010
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Hypogonadism
ESPRIT Study in Hypogonadal Men
Observational study with AndroGel®, Testosterone 1% gel therapy (ESPRIT) in hypogonadal men in the community over 6 months.
- Trial name
- NCT01143818
- Testing
- AndroGel (testosterone gel) 1%
- Where
- 331 sites in Canada, Croatia and 7 more
- Volunteers
- 1,053 people
- Sponsor
- Abbott
Hypoactive Sexual Desire Disorder
2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an optional Open-label Extension to evaluate the efficacy of bremelanotide (BMT), administered subcutaneously (SC) on an as needed basis for the…
- Trial name
- HSDD (NCT02338960)
- Testing
- Bremelanotide
- Where
- 91 sites in United States, Canada
- Volunteers
- 714 people
- Sponsor
- Palatin Technologies, Inc
Sexual Dysfunctions, Psychological
Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in North America
The objective of this trial is to assess the safety and efficacy of 24-week course of flibanserin for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in naturally postmenopausal women.
- Trial name
- NCT01057901
- Testing
- Flibanserin
- Where
- 100 sites in United States, Canada
- Volunteers
- 748 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Sexual Dysfunctions, Psychological, Depression
12 Week Safety Trial of Flibanserin in Depressed Women Taking an SSRI or SNRI With Decreased Sexual Desire and Distress
The current trial will explore the safety of flibanserin in combination with Selective Serotonin Reuptake Inhibitors or Norepinephrine Serotonin Reuptake Inhibitors in a representative population of women with depressive and…
- Trial name
- NCT01040208
- Testing
- flibanserin 50 mg to 100 mg qhs, flibanserin 100 mg qhs
- Where
- 42 sites in United States
- Volunteers
- 111 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Sexual Dysfunctions, Psychological
Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder
This trial is designed to assess the safety and efficacy of flibanserin in the treatment of premenopausal women with Hypoactive Sexual Desire Disorder (HSDD) that meets standard diagnostic criteria.
- Trial name
- NCT00360555
- Testing
- flibanserin, flibanserin 50mg, flibanserin 100mg
- Where
- 77 sites in United States, Canada
- Volunteers
- 1,584 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Sexual Dysfunctions, Psychological
24-week Placebo-controlled Trial of Flibanserin Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder
This trial is designed to assess the safety and efficacy of flibanserin in the treatment of premenopausal women with Hypoactive Sexual Desire Disorder (HSDD) that meets standard diagnostic criteria.
- Trial name
- NCT00360529
- Testing
- flibanserin
- Where
- 54 sites in United States, Canada
- Volunteers
- 880 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Sexual Dysfunctions, Psychological
Flibanserin Versus Placebo in Premenopausal Women With HSDD
To establish efficacy of Flibanserin 50 Milligrams Daily and 100 Milligrams Daily in 6-month treatment, vs placebo for Hypoactive Sexual Desire Disorder in premenopausal European women.
- Trial name
- NCT00491829
- Testing
- 50 mg qhs, 100 mg
- Where
- 86 sites in Austria, Belgium and 11 more
- Volunteers
- 945 people
- Sponsor
- Sprout Pharmaceuticals, Inc